Wyeth's Redux, Mazanor obesity treatments recommended for high risk patients -- guidelines.
REDUX, PONDIMIN AMONG PHARMACOLOGIC THERAPIES RECOMMENDED FOR OBESE PATIENTS at "high, very high and extremely high health risk" in obesity treatment guidelines developed by the American Obesity Association and Shape Up America. "Dexfenfluramine is the first antiobesity agent approved" by FDA "for both weight loss and maintenance of weight loss," the guidance notes. The drug also has the "potential to provide an early indication of patient responsiveness, as an analysis of clinical data shows that 60% of patients who responded in the first four weeks of treatment lost 10% of their initial body weight after one year of treatment."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth